KORU Medical reports Q2 adjusted EPS 1c, consensus (2c)

Reports Q2 revenue $10.2M, consensus $9.46M. “We achieved a milestone this quarter, surpassing $10 million in revenue for the first time and delivering our sixth consecutive quarter of double-digit growth,” said Linda Tharby, president and CEO of KORU Medical (KRMD). “Strategically, we continued to outperform the strong SCIg market through global share gains, advanced our international expansion, and submitted a 510(k) filing to add a new drug to our Freedom Infusion System. Operationally, we delivered positive adjusted EBITDA, reflecting our disciplined execution and focused capital allocation, while continuing to invest in strategic growth areas. We believe this performance positions us well to drive continued shareholder value as we scale.”